EGFR and non-small cell lung carcinoma: The primary objective of this study is to investigate the efficacy of EGFR‐TKI combined with an angiogenesis inhibitor (apatinib) in patients with slow progression of NSCLC previously treated with EGFR‐TKI monotherapy (including erlotinib, gefitinib, and icotinib).